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Attenuating the function of protein arginine methyltransferases (PRMTs) is an objective for
the investigation and treatment of several diseases including cardiovascular disease and
cancer. Bisubstrate inhibitors that simultaneously target binding sites for arginine substrate
and the cofactor (S-adenosylmethionine (SAM)) have potential utility, but structural
information on their binding is required for their development. Evaluation of bisubstrate
inhibitors featuring an isosteric guanidine replacement with two prominent enzymes
PRMT1 and CARM1 (PRMT4) by isothermal titration calorimetry (ITC), activity assays and
crystallography are reported. Key ﬁndings are that 2-aminopyridine is a viable replacement
for guanidine, providing an inhibitor that binds more strongly to CARM1 than PRMT1.
Moreover, a residue around the active site that differs between CARM1 (Asn-265) and
PRMT1 (Tyr-160) is identiﬁed that affects the side chain conformation of the catalytically
important neighbouring glutamate in the crystal structures. Mutagenesis data supports its
contribution to the difference in binding observed for this inhibitor. Structures of CARM1 in
complex with a range of seven inhibitors reveal the binding modes and show that inhibitors
with an amino acid terminus adopt a single conformation whereas the electron density for
equivalent amine-bearing inhibitors is consistent with preferential binding in two conforma-
tions. These ﬁndings inform the molecular basis of CARM1 ligand binding and identify
differences between CARM1 and PRMT1 that can inform drug discovery efforts.
Introduction
Protein arginine methyltransferases (PRMTs, E.C. 2.1.1.125) catalyse the transfer of methyl groups
from S-adenosylmethionine (SAM) to arginine residues of target proteins, giving a pattern of nitrogen
methylations dictated by enzyme type (Figure 1A). Hydrogen bonding N-H moieties are replaced by
hydrophobic N-methyl groups to effect protein–protein interactions as a result. Co-activator associated
arginine methyltransferase (CARM1, or PRMT4) targets substrates that contain proline-rich sequences
rather, than the GGRGG sequences favoured by PRMT1. PRMTs are involved in the regulation of
numerous cellular processes including chromatin function [1–8], RNA processing [9,10], and
DNA-damage response [11–13]. Co-activation of gene transcription is effected by methylation of
histone arginines: H4R3 by PRMT1; or H3R17 and H3R26 by CARM1, for example. Meanwhile,
methylation of RNA binding proteins is involved in the regulation of protein translation. An increas-
ing body of evidence links PRMT dysregulation to disease processes, including asthma, kidney and
cardiovascular disease and cancer [14–17], underlining the need for potent, well-characterised PRMT
inhibitors as molecular probes and potential therapeutic agents. CARM1 is overexpressed in breast
[18], prostate [19], lung [20], liver [21], and colorectal cancer [22]. CARM1 inhibition has been
shown to slow tumour growth in a multiple myeloma xenograft model [23], inhibit liver cancer
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cell proliferation [21] and impair AML initiation and proliferation [24]. PRMT1 on the other hand catalyses
the majority of methylation events in the cell and is overexpressed in breast cancers, prostate cancers, and
leukemia [15].
PRMT inhibitors reported to date can be broadly categorised into SAM analogues (including the pan-
methyltransferase inhibitors sinefungin (3) and S-adenosyl homocysteine (2), (Figure 1A)), substrate peptide
analogues [25–28], and structures optimised from high throughput screening hits [29–32]. Promising CARM1
inhibitors include EPZ022302/EZM2302 (a 6 nM CARM1 inhibitor with anti-tumour activity in vivo) [23] and
TP-064 (IC50 < 10 nM against CARM1 and >100-fold selective over other methyltransferases) [32]. In both
cases, ternary crystal structures with CARM1-SAH showed the inhibitor to occupy the substrate-binding pocket
with kinetic data supporting noncompetitive inhibition with respect to both SAM and peptide substrate
[23,32]. Alternatively, inhibitors may occupy both the SAM and arginine binding sites (Figure 1B) [28,33–35].
A number of such inhibitors that target CARM1 feature amino adenosine linked to modiﬁed cytosine moieties
that occupy the SAM and arginine binding site, respectively [36]. The most potent of these inhibitors displayed
an IC50 of 1.5 mM against CARM1, and was 100-fold less potent against PRMT1. Design of selective inhibitors
is challenging however, since the residues involved in SAM and substrate arginine binding are largely conserved
in the nine PRMTs encoded in the human genome, particularly between type I family members [37]. In line
with recent advances [38], the development and structural investigation of rationally designed bisubstrate
inhibitors remains a desirable route to identify individual residue variations that may contribute to selective
inhibition of CARM1 over PRMT1 for example.
Figure 1. PRMT classiﬁcation and inhibitor structures.
(A) Arginine methylation patterns deposited by PRMTs. The PRMTs are classiﬁed as type 1, 2 or 3 according to whether
they generate monomethylarginine (MMA), symmetric dimethyl arginine (sDMA) or asymmetric dimethylarginine (aDMA);
(B) Structures of bisubstrate azo-SAM inhibitors from the present study (4–10) and those reported previously by van Haren
et al. [28,33].
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).788
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Bisubstrate inhibitors featuring guanidinium and aza-adenosylmethionine moieties joined by alkyl linkers
were previously reported. Longer linkers appeared to confer a degree of selectivity between CARM1 and
PRMT1, which was rationalised based on docking studies [34]. Van Haren et al. have also explored this
approach by 50-hydroxyl group of adenosine with a methylguanidinium group, which resulted in a compound
with 100-fold selectivity for CARM1 over PRMT1 [33]. Extending the guanidinium group to a CARM1
substrate peptide achieved a greater degree of selectivity for CARM1 over PRMT1 (IC50 values of 0.09 and
25.5 mM, respectively for the most selective compound) [28]. Whilst promising in their apparent selectivity, a
key drawback of such peptide-fused mimics is their potential susceptibility to proteolysis, which limits their
utility in cellular assays and in vivo applications.
Novel non-peptidic bisubstrate inhibitors and crystal structures of their complexes with CARM1 are reported
here. Isothermal titration calorimetry and activity assays allowed measurement of afﬁnity and inhibition of both
PRMT1 and CARM1. Data herein shows that replacement of the guanidinium group with an aminopyridine or
aminopyrimidine enhances the inhibitors’ afﬁnity for CARM1 but not PRMT1. The inﬂuence of a speciﬁc
active site residue on the orientation of the catalytic glutamate and inhibitor binding was evaluated with
CARM1 N265Y mutant protein; crystal structures revealed that this mutation affects the conformation of key
residues at the substrate-binding site.
Experimental procedures
Constructs, protein expression and puriﬁcation
The catalytic domain of human CARM1, residues 135 to 479 (CARM1135–479; isoform 3, UniProt accession
code Q86X55) was cloned into the vector pMALX(E) (a modiﬁed pMAL-c2x vector, kindly provided by Lars
Pederson [39]) using restriction sites NotI and HindIII with the addition of a C-terminal His-tag and a TEV
cleavage site directly upstream of the CARM1 sequence. The ﬁnal sequence expressed was MBP-AALAAAQT-
NAAAENLYFQ-CARM1135–479-HHHHHH. CARM1135–479 was expressed in BL21-CodonPlus (DE3)-RIL cells
(Agilent) at 20°C after induction with 0.4 mM IPTG. After 20 h, cells were harvested by centrifugation, resus-
pended in 50 mM Tris, 300 mM NaCl, 20 mM imidazole, 5% v/v glycerol at a pH of 7.5 (buffer A), lysed by
sonication, and the lysate clariﬁed by centrifugation. CARM1135–479 was puriﬁed by nickel afﬁnity chromatog-
raphy (5 ml HiTrap chelating HP column, GE Healthcare) using buffer A with a gradient elution of 20 to
500 mM imidazole over 20 column volumes. The protein was concentrated to ∼1 mg/ml and cleaved with TEV
protease to remove the MBP tag. The cleaved protein was then separated from TEV protease and the MBP tag
by gel ﬁltration (HiLoad Superdex S200 16/60 PG, GE Healthcare), fractions containing the protein concen-
trated and 1 mg/ml aliquots either used directly or ﬂash frozen and stored at −80°C until further use.
Approximately 0.2 mg CARM1 catalytic domain was obtained per litre of bacterial culture.
Human PRMT1, residues 22 to 361 (PRMT122–361; isoform 1/splice variant 2, Uniprot accession code
Q99873), was cloned into vector pET-26b(+) using restriction sites NdeI and XhoI. PRMT122–361 was expressed
and puriﬁed as outlined for CARM1, except that buffers were at pH 8.0 and the His-tagged protein obtained
from nickel afﬁnity chromatography was concentrated and loaded directly onto a gel ﬁltration column.
Approximately 2 mg of PRMT1 were obtained per litre of bacterial culture.
The sequence for histone peptide H4 residues 1 to 21 (herein referred to as H41–21) and the sequence for
histone peptide H3, residues 3–31 (herein referred to as H33–31) were cloned into a modiﬁed pET-21a(+)
vector containing an N-terminal GB tag and a C-terminal His-tag. H41–21 and H33–31 were expressed and puri-
ﬁed as described above for PRMT1 except that the buffers had a lower NaCl concentration of 150 mM.
Aliquots of the peptides were concentrated to 400 mM, ﬂash frozen, and stored at −80°C until needed.
Inhibitor compounds
Synthesis of 4 and 7 was described previously [34], 5, 6, 8, 9 and 10 were prepared similarly and are described
in the Supplementary Information.
Crystallisation
Co-crystallisations of CARM1135–479 with inhibitors were carried out in 24-well plates using the sitting-drop
vapour diffusion method. In the case of compound 5, the CARM1 catalytic domain was concentrated to
1.7 mg/ml, followed by addition of a 500 mM aqueous stock solution of inhibitor such that the ﬁnal protein
concentration was 28 mM and the ﬁnal ligand concentration was 167 mM. Co-crystallisations were performed
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 789
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by mixing 1 ml of the protein-inhibitor solution with 1 ml of a solution containing 0.1 M Bis-tris propane-Cl at
a pH of 7.0, 0.02 M potassium phosphate and 22% (w/v) PEG 3350 in sitting drop trays. Trays were incubated
at 20°C and crystals grew within one week. Co-crystallisations with the other inhibitors were carried out with
similar ligand concentrations and temperatures, but the crystallisation conditions, and CARM1 concentrations
varied as detailed in Supplementary Table S1. Crystals were cryoprotected in the well solution supplemented
with 30% (v/v) glycerol and 20% (w/v) PEG 3350 prior to cryocooling in liquid nitrogen.
Data collection, structure determination and reﬁnement
Datasets were collected at the European Synchrotron Radiation Facility, Grenoble, France or Diamond Light
Source, Harwell, Oxford using beamlines I02, ID30B and ID30A-1. Crystals belong to space group P21212, with
four monomers in the asymmetric unit. All CARM1 structures were solved by molecular replacement using
Phaser MR [40]. The structure of CARM1 in complex with sinefungin (3) and an inhibitor (PDB code 2Y1X)
[41] or subsequently CARM1 in the CARM1–5 complex structure were used as search models in molecular
replacements (with the ligands removed). Model building was carried out in COOT [42] and reﬁnement was
carried out with Phenix [43] and Refmac [44]. Ligand restraints were generated using eLBOW [45]. All struc-
tural images were generated using The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC.
Parameters for data collection, structural reﬁnement and validation are listed in Supplementary Table S2.
Enzymatic assays
Methylation reactions contained PRMT122–361 (160 nM), H4(1–21) (40 mM) and adenosyl-L-methionine,
S-[methyl-3H] (PerkinElmer, NET155H250UC) at a ﬁnal concentration of 0.23 mM, in phosphate buffered saline
buffer at pH 7.3 in the presence of the different inhibitors. For IC50 curves, a minimum of 10 inhibitor concentra-
tions were used, and experiments were carried out in duplicate. The reactions were initiated by addition of
adenosyl-L-methionine, S-[methyl-3H] and incubated at 30°C after mixing. After 60 min, optimised for signal to
noise ratio in the linear region, each reaction mixture was transferred by pipette onto a P81 phosphocellulose
paper square (PerkinElmer) and immediately immersed in a stirred solution of trichloroacetic acid (10% w/v).
The phosphocellulose squares were washed for 3 × 10 min, replacing the 10% trichloroacetic acid after each wash.
A ﬁnal wash was carried out with 95% ethanol, the squares removed and allowed to dry. Incorporation of tritium
into the histone substrate was determined by liquid scintillation counting. For each inhibition series, a no-substrate
control reaction was included, which contained water in place of the histone substrate. This data point was
included in the data used to ﬁt the curve by setting the x-value (log[I]) to 4.0. A no-inhibitor control was also
included in the data, with the x-value (log[I]) set to −3.0. These control samples were also run in duplicate.
CARM1 methylation reactions were carried out using 0.23 mM adenosyl-L-methionine, S-[methyl-3H],
320 nM CARM1135–479 and 120 mM histone substrate (H3(3–31)). Since CARM1 automethylates, a no-enzyme
control was used as the maximum inhibition sample (log[I] set to 4.0). Data were analysed in GraphPad Prism
7 and ﬁt using non-linear regression using the ‘log(inhibitor) vs. response — variable slope (four parameters)’
function with no constraints. The concentrations of inhibitor solutions were determined using a NanoDrop
1000 v3.7, using the molar extinction coefﬁcient at 260 nm for S-adenosyl homocysteine (ε = 15 400 M−1 cm−1).
2-alkylaminopyrimidines (8) and 2-alkylaminopyridines (9 and 10) absorb at 260 nm with extinction coefﬁ-
cients of <15 400 M−1 cm−1 [46,47]. The concentrations of 8, 9 and 10 may therefore have been overestimated
by up to two-fold with corresponding effect on the estimated Kd and IC50 values for these inhibitors.
Isothermal titration calorimetry (ITC)
Titrations were carried out using a MicroCal PEAQ-ITC Isothermal Titration Calorimeter (Malvern) or
MicroCal iTC200 (Malvern) in the case of the titration of 5 into PRMT122–361. Data analysis was carried out
using MicroCal PEAQ-ITC Analysis Software. Inhibitors were dissolved in gel ﬁltration buffer to concentrations
between 150 and 736 mM as suitable for ITC assays. An amount of 2.4 ml injections of inhibitor solutions into
the protein solution at concentrations between 21 and 121 mM were performed, at 25°C. Control titrations
were carried out by titrating the inhibitor solution into the buffer solution. The control heats of dilution were
subtracted from binding experiments prior to curve ﬁtting using a one-site binding model with ﬁtted offset.
The raw data and integrated ﬁtted curves are shown in Supplementary Figures S2, S4, S6–S8 derived thermo-
dynamic parameters are listed in Supplementary Tables S3, S4. Protein concentrations were determined by UV
absorbance at 280 nm (with a NanoDrop 1000 v3.7) using extinction coefﬁcients at 280 nm determined by the
ExPASy ProtParam online tool. The protein concentrations calculated in this manner were shown to be in
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).790
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good agreement with the concentration determined by Bradford assay using a BSA standard. Inhibitor concen-
trations were determined as for activity assays. In two instances (7 into PRMT1 and 10 into CARM1 N265Y),
low c-value curves necessitated ﬁxing the stoichiometry prior to curve-ﬁtting.
Results
Inhibitors of both PRMT1 and CARM1 that bind in a bisubstrate manner
Putative bisubstrate inhibitors 4, 5 and 6 containing amines and arginine-mimicking alkylguanidinium groups
with chain lengths increasing from three to ﬁve methylenes respectively (Figure 1B) were assessed for their
potential to bind and inhibit CARM1 and PRMT1. A radiometric methylation assay was used to assess the
inhibitory strength of this series of inhibitors (Supplementary Figure S1) and resulting IC50 values are shown in
Table 1, entries 1–3. Comparison of IC50 values for inhibitors 4–6 revealed a modest decrease in potency (2.3
to 17.7 mM) against CARM1135–479 as the length of the alkyl linker between the aminoadenosine and guanidi-
nium groups is increased from 3 to 5 methylene units. No such trend was observed for PRMT1, with inhibitors
displaying similar IC50 values for PRMT122–361 (7.2–11.8 mM) as CARM1. Isothermal titration calorimetry was
then used to determine the dissociation constants of this inhibitor series for PRMT1 and CARM1 (Table 1;
Supplementary Figure S2; Supplementary Table S3). The resultant Kd values showed a similar pattern to the
IC50 values, with all inhibitors binding with low micromolar afﬁnity to both PRMT1 and CARM1 and again,
CARM1 displayed a slight preference for a shorter alkyl linker length (Table 1). Inhibitor 7 (the amino acid
analogue of 6), was also evaluated and found to bind and inhibit both PRMT1 and CARM1 to a similar extent
(Table 1; Supplementary Figure S2; Supplementary Table S3).
Table 1 Kd and IC50 values for series of inhibitors (4–10) and SAH against PRMT1 and
CARM1 measured using ITC and enzyme activity assays, respectively
Inhibitor
Kd ± standard error (mM) IC50 (95% confidence interval) (mM)
PRMT1 CARM1 PRMT1 CARM1
4 10.2 ± 0.996 3.32 ± 0.335 7.2 (3.5–15.0) 2.3 (1.8–3.0)
5 4.02 ± 0.453 7.18 ± 0.557 11.8 (9.0–15.5) 8.7 (6.9–10.8)
6 9.99 ± 1.89 9.80 ± 1.83 11.6 (4.9–27.2) 17.7 (13.5–23.2)
7 32.2 ± 3.531 38.1 ± 9.61 22.0 (14.4–33.5) 24.1 (15.4–37.6)
8 10.2 ± 4.21 2.30 ± 0.162 22.0 (15.7–30.8) 0.7 (0.5–1.0)
9 15.3 ± 1.57 1.14 ± 0.411 11.1 (5.6–21.8) 0.3 (0.1–1.1)
10 43.7 ± 14.92 1.11 ± 0.132 25.3 (17.3–37.0) 0.8 (0.6–1.0)
SAH 0.709 ± 0.057 0.775 ± 0.111 0.5 (0.2–1.0) 0.2 (0.1–0.4)
1Stoichiometry fixed to 0.5.
2This Kd is derived from a competition experiment with SAH as the Kd was not accessible through direct
titration.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 791
Biochemical Journal (2020) 477 787–800
https://doi.org/10.1042/BCJ20190826
D
ow
nloaded from
 https://portlandpress.com
/biochem
j/article-pdf/477/4/787/868731/bcj-2019-0826.pdf by U
niversity of N
ottingham
 user on 06 M
arch 2020
Co-crystallisation trials were carried out with the aim of determining the binding mode and whether the mole-
cules bound as bisubstrate inhibitors. The catalytic core of CARM1 was crystallised in the presence of amine-
guanidine inhibitors 4, 5, 6 and 7, and the structures solved by molecular replacement. Crystals belonged to space
group P 21212 with two CARM1 dimers in the asymmetric unit, in line with CARM1 structures that have been
previously reported [23,41,48]. Data collection and reﬁnement statistics are shown in Supplementary Table S2.
Electron density corresponding to each of these respective inhibitors was clearly observed in the active site
(Figure 2A–D). Superposition of the CARM1 complex structures with a published structure of CARM1 in
complex with SAM-mimic sinefungin (3) and a histone 3 tail substrate (PDB code 5DX0 [48]) revealed that
Figure 2. Crystal structures of inhibitors 4, 5, 6 and 7 in complex with CARM1.
(A–D) 2mFo-DFc electron density maps contoured at σ = 1 for 4 (a), 5 (b), 6 (c) and 7 (d) in ball-and-stick representation bound
in the CARM1 active site. Polar contacts assigned using PyMol are indicated with blue dashed lines and residues involved in
SAM and substrate arginine binding (and those involved in putative polar contacts) are shown. (E) Superposition of 4 (orange),
5 (yellow), 6 (green) and 7 (cyan) structures as bound to CARM1 with a published structure of CARM1 in complex with histone
3 and sinefungin (magenta, PDB code 5DX0 [48]).
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).792
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the positions of the adenosine moieties of inhibitors 4–7 in the CARM1 active site closely match that of sine-
fungin (Figure 2E). The alkylguanidinium group also extends into the arginine binding channel as designed,
conﬁrming the bisubstrate nature of inhibition. In comparison with the position of H3 Arg-17 (the arginine
targeted for CARM1 methylation), the guanidinium groups of all inhibitors reach beyond Glu-257 (which
forms a bidentate interaction with the substrate arginine η nitrogens) and Glu-266 (that forms a hydrogen
bond to the ε nitrogen of substrate arginines) [48]. The B factors of the guanidinium groups of 4, 5 and 6 and
7 are relatively high compared with the other ligand atoms, which may suggest that this group retains some
ﬂexibility when bound in the active site (Supplementary Figure S3).
Substitution of the guanidinium group for a 2-aminopyridine improves binding
to CARM1 but not PRMT1
Inhibitors 8, 9 and 10 (Figure 1B) were synthesised with a view to replacing the guanidinium group with less
polar 2-aminopyrimidine (8) or 2-aminopyridine (9, 10) isosteres. Binding afﬁnities for these molecules with
CARM1 (Kd of 2.30 mM (8), 1.14 mM (9) and 1.11 mM (10), Table 1; Supplementary Figure S4; Supplementary
Table S3) were found to be comparable with that obtained for guanidine inhibitor 4 (Kd 3.32 mM). An activity
based assay returned IC50 values about ﬁve-fold lower (0.7 mM (8), 0.3 mM (9), 0.8 mM (10)), than the guanidi-
nium substituted analogue (2.3 mM for 4), Table 1 and Supplementary Figure S5. The same molecules (8–10)
were ∼30-fold less potent inhibitors of PRMT1.
To gain insight into the binding mode of these ligands, 8, 9 and 10 were co-crystallised with CARM1 and
the resulting structures solved by molecular replacement. Examination of active site electron density maps
showed that in all cases the position of the adenosine moiety was the same as observed earlier in structures of
CARM1 in complex with 4–7 (Figure 3A,B). It was apparent that inhibitors 8 and 9 occupy two conformations
within the CARM1 active site, in which the amine and aromatic groups alternately occupy the binding channels
of the substrate arginine and the SAM amino acid (Figure 3A,D). Interestingly, introduction of a carboxylate
group (as in 10) resulted in a clear preference for one binding pose within the active site (Figure 3B). This may
be attributed to an interaction between Arg-168 and the inhibitor carboxylate, which mimics the carboxylate
group of SAM. ITC experiments with 10 revealed that introduction of this carboxylate group does not affect
the afﬁnity for CARM1 (Table 1; Supplementary Figure S4; Supplementary Table S3).
No binding of 10 to PRMT1 directly (IC50 of 25.3 mM) was observed using ITC under the same conditions
as for the other inhibitors (Table 1). To exclude the possibility that 10 inhibits PRMT1 through nonspeciﬁc
destabilisation, SAH (2) was titrated into a solution of PRMT1 and 10. The presence of 10 in the cell resulted
in an increase in the apparent Kd of SAH (2) for PRMT1, while the stoichiometry remained unchanged
(Supplementary Table S4). Fitting the resulting isotherm using a competitive binding model thus provided a
Kd∼ 43.7 mM estimate of 10 for PRMT1 (Supplementary Figure S6).
CARM1 Asn-265 may contribute to the preferential binding of heteroaromatic
inhibitors
To explore differences between the CARM1 and PRMT1 active sites, attention focused on two residues in the
CARM1 substrate-arginine binding channel (Figure 4). The ﬁrst, Asn-161 (Glu-55 in PRMT1), was identiﬁed
as a possible cause for preferential binding of 5C amino acid/guanidine inhibitor 7 to PRMT1 observed previ-
ously [34]. A difference in sequence at position CARM1 Asn-265, which corresponds to Tyr-160 in PRMT1
was identiﬁed by analysing structural alignments of PRMT1 and CARM1. We hypothesised that the residue in
this position may affect the conformation of neighbouring glutamate Glu-266 (Glu-161 PRMT1), which is
critical for orienting the substrate arginine residue for methylation and is in close proximity to the aromatic
rings in compounds 9 and 10. This glutamic acid residue adopts a different conformation in CARM1
compared with PRMT1 crystal structures (Figure 4B,D). CARM1 Asn-265 may therefore affect the Glu-266
conformation and, as a consequence, its interactions with the aromatic rings in compounds 9 and 10. In order
to evaluate the possible effects of these two sequence differences CARM1 residues Asn-161 and Asn-265 were
mutated into the corresponding PRMT1 residues, Glu and Tyr located at equivalent positions, respectively
(Figure 4).
The mutation CARM1 N161E renders the rim of the substrate arginine binding pocket more like PRMT1.
Inhibitors (8, 9, 10 and SAH) showed marginally greater afﬁnity (Kd 0.133–1.11 mM) for the CARM1 N161E
mutant compared with wild-type (WT) (0.774–2.30 mM, Table 2; Supplementary Figures S7, S8). The second
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mutation, CARM1 N265Y renders the substrate arginine-binding pocket more PRMT1-like. A modest decrease
in the afﬁnity of 8, 9 and SAH for CARM1 N265Y compared with WT was observed while the Kd increased
substantially from 1.11 to 143 mM for inhibitor 10 (Table 2; Supplementary Figure S8). These observations
reinforce the notion that interactions between the aminopyridine and substrate binding channel are responsible
for the preferential binding of 10 to CARM1 over PRMT1. To investigate the structural origin of this effect,
CARM1 N265Y was co-crystallised with 10. As hypothesised the resulting structure revealed a conformational
change in Glu-266, in which the glutamate adopts a conformation whereby the plane of the carboxylate group
is almost parallel to the phenol side chain of Tyr-265 (Figure 4C,D).
Figure 3. Crystal structures of inhibitors 9 and 10 in complex with CARM1.
(A) 2mFo-DFc electron density maps contoured at σ = 1 for two monomers within the asymmetric unit of the CARM1·9 complex
structure. Polar contacts as computed by PyMol are indicated by blue dashed lines and residues involved in SAM and
substrate arginine binding are shown in stick representation and are labelled; (B) 2mFo-DFc electron density map of inhibitor 10
contoured at σ = 1. Polar contacts and relevant residues are shown as for (A). All monomers within the asymmetric unit of the
CARM1·10 structure have similar electron density for 10 corresponding to the same ligand conformation as depicted in (B).
(C) binding pockets of adenosine (orange dashes) and SAM amino acid (red dashes), and substrate binding channel
(teal dashes) generated using a CARM1·H3 tail peptide·sinefungin complex crystal structure (PDB code 5DX0) [48].
(D) Superposition of complex structures with ligands 8 (pale pink, two conformations observed are shown), 9 (purple, two
conformations observed are shown) and 10 (blue, single conformation) with a structure of CARM1 in complex with histone 3
and sinefungin (magenta, PDB code 5DX0) [48].
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).794
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Discussion
In this study, the binding of a novel series of non-peptidic bisubstrate inhibitors against both PRMT1 and
CARM1 has been characterised. Unexpectedly, the length of a methylene linker between the guanidinium and
azo adenosylmethionine moieties that comprise a subset of these inhibitors was not a determining factor for
PRMT1 and CARM1 afﬁnity, nor the position of the guanidinium group within the active site of CARM1. On
testing an analogous series of amino acid-guanidine inhibitors, we previously observed a signiﬁcant reduction
in afﬁnity for CARM1 on increasing the alkyl linker length from 3 to 5 methylene units [34]. In contrast with
previous results, a weak interaction of the 5C amino acid-guanidine 7 with both PRMT1 and CARM1 was
detected, exhibiting IC50 and Kd values of 20–40 mM. Binding of 7 to CARM1 is also evidenced by the clear
Figure 4. Structural rationale for mutagenesis and crystal structure of 10 with CARM1-N265Y.
(A) Superposition of CARM1·10 complex structure (white) with a PRMT1 structure (cyan) in complex with SAH (not shown)
(PDB code 1OR8 [50]). The side chains of residues targeted for mutagenesis are shown as sticks. (B) Zoomed-in view of
position of amino acid sequence differences between PRMT1 and CARM1 investigated. (C) Superposition of CARM1·10
complex structures with (blue) and without (white) the N265Y mutation. Every monomer within the asymmetric unit has been
superposed. (D) Superposition of all CARM1(WT) monomer structures (white), all CARM1-N265Y monomers (teal) and PRMT1
(PDB code 1OR8, pink [50]).
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 795
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electron density in a co-crystal structure (Figure 2D). The apparent difference between these results and those
previously reported regarding inhibitor 7 may be a result of the different CARM1 constructs used. In order to
be able to compare trends from the measured dissociation constants by ITC and IC50 values we focused on the
catalytic core of CARM1 [34]. It has been reported that indole and pyrazole CARM1 inhibitors displayed dif-
ferent relative potency when tested using an activity assay with GST-tagged full-length protein and ITC with
the catalytic core [41]. It is possible that the presence of the GST-tag or additional regions of CARM1 outside
of the catalytic core inﬂuence inhibitor binding. Elucidating a structure of full-length CARM1 in complex with
inhibitors or its substrates, and determining the precise role of the domains ﬂanking the catalytic core, will aid
the design of CARM1 inhibitors. The bisubstrate nature of the inhibitors described herein necessitates care in
interpretation of IC50 data. In the absence of detailed kinetic analysis (allowing conversion of IC50 values to
Kis) an interpretation of selectivity of an inhibitor between different enzymes based on IC50 data [49] has to be
treated with caution. Since such analysis is beyond the scope of the present study, Kd measurements (which do
not suffer this complication) were obtained to enable direct comparison of the afﬁnity of the inhibitor series
for PRMT1 versus CARM1.
While these experiments were being conducted, binding studies on a related inhibitor series were reported.
[28,33] Comparing the trends of reported IC50 values suggests that the optimal number of atoms between the 40
ribose carbon and the guanidine group is three (equivalent to a 1 methylene linker in our inhibitors), or two
atoms joined by a double bond. The differing assay conditions and inhibitor structures mean that these values
cannot be directly compared with ours. Nonetheless, the high potency achieved with these shorter linker
lengths, in combination with the inhibition and crystallographic data reported herein (Figure 2), suggest that
the 3 to 5 methylene alkylguanidines in our inhibitors could be shortened to a methylguanidine group to better
align the inhibitor guanidine for interaction with CARM1’s active site glutamates, thus improving binding.
Both, inhibitors 9 and 10 displayed preferential binding for CARM1 over PRMT1. For 10, a Kd estimate of
43.7 mM for PRMT1 (IC50 of 25.3 mM) was determined through a competition binding experiment as direct
binding upon titrating 10 into PRMT1 was not observed, presumably because the heat change associated with
ligand binding was below the limit of detection). This Kd value is broadly consistent with the IC50 value, and
indicates that the inhibitors 9 and 10 binding more strongly to CARM1 over PRMT1 by ∼15- and ∼40-fold,
respectively (as judged by ITC). This degree of selectivity provides a promising framework for the development
of higher potency chemical probes for cellular assays. Interestingly, nine structures have recently been added to
the PDB of CARM1 from Mus musculus in complex with different aromatic-containing bisubstrate inhibitors
(PDB codes 5TBJ, 5TBI, 5TBH, 5LV3, 5LV2 [36] and 5ISB 5IS9, 6DVR and 6D2L [38]). Superposition of these
structures with the CARM1–9 complex structure (Supplementary Figure S9) revealed reasonably good overlap
of 9’s aminopyridine group with the aromatic groups of these inhibitors, particularly in the SAM carboxylate
binding pocket (i.e. superposition with SKI-72, Supplementary Figure S9). The presence of aromatic groups in
this pocket further supports our ﬁnding that 8 and 9 adopt alternate conformation in which the aromatic
group may occupy either the substrate binding channel or the SAM carboxylate binding pocket (Figure 3). The
observed trend towards increased potency for CARM1 by using hydrophobic guanidine isosteres will be useful
in the pursuit of additional CARM1 chemical probes.
Mutagenesis studies revealed that CARM1 Asn-265 may be important for the binding of inhibitors with
hydrophobic guanidine isosteres (9 and 10). The effect of this mutation on the position of Glu-266 in the
crystal structure of CARM1 N265Y is notable. It has been suggested that the corresponding glutamate
Table 2 Kd values for isosteric inhibitors and 5C amino acid 7 against CARM1 single site
PRMT1-mimicking mutants N161E and N265Y measured using ITC
CARM1
Kd ± standard error from curve fitting (mM)
7 8 9 10 SAH
WT 38.1 ± 9.61 2.30 ± 0.162 1.14 ± 0.411 1.11 ± 0.132 0.774 ± 0.111
N161E 8.18 ± 0.482 1.11 ± 0.201 0.354 ± 0.034 0.181 ± 0.017 0.133 ± 0.022
N265Y -1 5.18 ± 1.86 3.26 ± 0.458 143 ± 75.92 1.49 ± 0.063
1Not tested.
2Stoichiometry fixed to 1. Low sigmoidicity makes this value unreliable.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).796
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(Glu-161) in PRMT1 [50] is catalytically incompetent since it appears to be rotated away from the active site
(PDB code 1OR8) [48,50]. This was attributed to likely protonation of Glu-161 due to the low pH at which the
crystals formed. However, these studies reveal that substitution of CARM1 Asn-265 with a tyrosine, as present
in PRMT1, results in a conformation of the glutamate side chain similar to PRMT1 in crystals grown at a pH
of 7.0. This suggests that this alteration in the glutamate conformation is predominantly a result of interaction
with the neighbouring tyrosine, rather than protonation of the side chain carboxylate. A sequence alignment of
human PRMTs (Figure 5A) reveals that PRMTs 1, 2, 3, 6 and 8 have aromatic side chains in this position (Y,
F, F, H, Y, respectively), while PRMTs 4, 5, 7 and 9 have non-aromatic side chains (N, N, G, G, respectively). A
superposition of available PRMT structures with tyrosine or phenylalanine adjacent to the conserved glutamate
(Figure 5B) shows that PRMT8, which has a tyrosine in this position exhibits a conformation of the neighbour-
ing glutamate similar to that seen in the CARM1-N265Y mutant. The glutamate side chains of PRMT2 and
PRMT3 (which have a phenylalanine at this position) are closer to that seen in WT CARM1. Further investiga-
tion will be required to determine the extent to which these sequence differences can be exploited for selective
PRMT inhibitor development.
Crystal structures (Figure 3) show that inhibitors 8 and 9, which feature terminal primary amines, may
adopt an alternative binding conformation that positions the aminopyridine group into the subsite that nor-
mally binds the amino acid terminus of SAM. In contrast, inhibitor 10 has an amino acid terminus and adopts
a single conformation that places the aminopyridine in the arginine-binding channel. This suggests that the
inhibitor carboxylate group may be required to ensure the arginine mimic occupies the desired pocket. Despite
conferring this apparent conformational preference, the carboxylate group does not appear to enhance the
afﬁnity of our series of inhibitors for CARM1, with 9 and 10 displaying similar Kd and IC50 values (Table 1).
Furthermore, addition of a carboxylate group to 5C guanidine-amine 3 (i.e. inhibitor 4) resulted in a slight
decrease in potency. A terminal amino acid group (as in 7 and 10), or appropriate isosteric replacement may
therefore be beneﬁcial for ensuring that the arginine mimicking group exclusively occupies the substrate
binding channel in a single binding mode, as achieved by SAM for catalysis.
Overall, these results demonstrate effective incorporation of isosteric replacement of guanidine for a less
polar 2-aminopyridine into bisubstrate PRMT inhibitors. Investigation of further isosteric replacements will be
required to achieve greater rigidity, potency and cell permeability displayed by current lead compounds.
Different binding for these inhibitors between CARM1 and PRMT1 prompted structural investigation which
revealed differences at equivalent positions in the substrate channels for these respective enzymes (i.e. Asn-265
in CARM1 or Tyr-160 in PRMT1). Further investigation of binding and potency for bisubstrate inhibitors with
Figure 5. Sequence conservation of CARM1-N265 across other PRMTs and position of substrate arginine-interacting
glutamic acid residue in PRMT structures.
(A) Sequence alignment of human PRMT active sites showing site of N265Y mutation generated using ClustalW and Box
Shade. The site targeted for mutagenesis is highlighted in yellow. Sites that show >50% consensus are shaded (black for
identical residues and grey for similar residues). Colour coding matches the structures shown in (B). (B) Superposition of
PRMT1 (1OR8, hot pink [50]), PRMT2 (5JMQ, yellow), PRMT3 (1F3L, green [51]) and PRMT8 (5DST, blue [52]) with CARM1
(WT) (bound to 9, light grey, all monomers in the asymmetric unit shown) and CARM1-N265Y (bound to 10, teal), which all
have a tyrosine or phenylalanine adjacent to the active site glutamate.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 797
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other PRMTs that feature these differences will help determine whether they can be exploited to confer selectiv-
ity to future inhibitor designs.
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